{
    "id": "00de799f-c9cb-42b7-8471-5bde35108200",
    "indications": "onyda xr indicated treatment attention deficit hyperactivity disorder ( adhd ) monotherapy adjunctive therapy central nervous system ( cns ) stimulant medications pediatric patients 6 years age older [ ( 14 ) ] .",
    "contraindications": "starting 0.1 mg onyda xr orally daily bedtime without food . may increased increments 0.1 mg per day weekly intervals . maximum recommended 0.4 mg daily bedtime . ( 2.1 ) substitute onyda xr clonidine products mg-per-mg basis differing pharmacokinetic profiles . ( 2.3 ) discontinuing , taper dose decrements 0.1 mg every 3 7 days avoid rebound hypertension . ( 2.4 )",
    "warningsAndPrecautions": "supplied onyda xr ( clonidine hydrochloride ) extended-release oral suspension 0.1 mg/ml light beige tan viscous suspension . onyda xr supplied carton . carton contains one bottle child resistant closure , oral dosing dispenser ( ) , press bottle adapter ( ) . bottle 30 ml ndc 24478-148-03 one ( 1 ) oral dosing dispenser one ( 1 ) press bottle adapter bottle 60 ml ndc 24478-148-04 one ( 1 ) oral dosing dispenser one ( 1 ) press bottle adapter bottle 120 ml ndc 24478-148-02 two ( 2 ) oral dosing dispensers two ( 2 ) press bottle adapters storage handling store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect light . store dispense onyda xr original bottle . dispense bottle adapter oral dosing dispenser supplied carton . bottles 30 ml 60 ml , discard unused onyda xr 30 days first opening bottle . 120 ml bottle , discard unused onyda xr 60 days first opening bottle .",
    "adverseReactions": "onyda xr contraindicated patients history hypersensitivity reaction clonidine . included generalized rash , urticaria , angioedema [ ( 5.4 ) ( 6 ) ] .",
    "ingredients": [
        {
            "name": "CLONIDINE HYDROCHLORIDE",
            "code": "W76I6XXF06"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "POLYVINYL ACETATE",
            "code": "32K497ZK2U"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "SODIUM POLYSTYRENE SULFONATE",
            "code": "1699G8679Z"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "organization": "NextWave Pharmaceuticals, Inc",
    "name": "ONYDA XR",
    "effectiveTime": "20250411",
    "indications_original": "ONYDA XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older [see Clinical Studies (\n                     \n                        14\n                     \n                     )].",
    "contraindications_original": "Starting dosage is 0.1 mg of ONYDA XR orally once daily at bedtime with or without food. Dosage may be increased in increments of 0.1 mg per day at weekly intervals. Maximum recommended dosage is 0.4 mg once daily at bedtime. ( 2.1 ) Do not substitute ONYDA XR for other clonidine products on a mg-per-mg basis because of differing pharmacokinetic profiles. ( 2.3 ) When discontinuing, taper the dose in decrements of no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension. ( 2.4 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  ONYDA XR (clonidine hydrochloride) extended-release oral suspension 0.1 mg/mL is a light beige to tan viscous suspension.\n                  ONYDA XR is supplied in a carton. Each carton contains one bottle with a child resistant closure, an oral dosing dispenser(s), and a press in bottle adapter(s). \n                  \n                     \n                     \n                     \n                     \n                        \n                           Bottle of 30 mL \n                           NDC 24478-148-03 \n                           One (1) oral dosing dispenser and one (1) press in bottle adapter \n                        \n                        \n                           Bottle of 60 mL\n                           NDC 24478-148-04\n                           One (1) oral dosing dispenser and one (1) press in bottle adapter\n                        \n                        \n                           Bottle of 120 mL\n                           NDC 24478-148-02\n                           Two (2) oral dosing dispensers and two (2) press in bottle adapters\n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light. \n                  Store and dispense ONYDA XR in the original bottle. Dispense with bottle adapter and oral dosing dispenser supplied in the carton. \n                  For the bottles of 30 mL and 60 mL, discard any unused ONYDA XR 30 days after first opening the bottle.\n                  For the 120 mL bottle, discard any unused ONYDA XR 60 days after first opening the bottle.",
    "adverseReactions_original": "ONYDA XR is contraindicated in patients with a history of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, and angioedema [see Warnings and Precautions (\n                     \n                        5.4\n                     \n                     ) and Adverse Reactions (\n                     \n                        6\n                     \n                     )]."
}